Deborah McBride
Women's Health · Fresno, CANPI 1114905205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,330 of the $2,917 with a category attached, or 79.9%. 14 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 40.8% of the total. Reporting peaked in 2023 at $1,416 and has fallen 71.8% since, to $399 in 2025. Among women's health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$1K
- Medtronic$827
- Astellas Pharma US Inc$276
- Urovant Sciences Inc$264
- Coloplast$75
- Convatec Inc.$56
- plus $228 from 8 others
What the payments were for
- Travel & lodging$39914%
- Food & beverage$2,33080%
- Education$1886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 105 | $1,191 |
| Medtronic | 9 | $827 |
| Astellas Pharma US Inc | 10 | $276 |
| Urovant Sciences Inc | 27 | $264 |
| Coloplast | 4 | $75 |
| Convatec Inc. | 3 | $56 |
| Boston Scientific | 1 | $55 |
| 180 Medical, Inc. | 2 | $48 |
| Mayne Pharma Commercial LLC | 3 | $38 |
| AbbVie | 1 | $23 |
| Bayer | 1 | $20 |
| Pfizer | 1 | $17 |
| Sagent Pharmaceuticals | 1 | $14 |
| Axonics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,917 in reported general payments places this provider in the 95th percentile of 480 women's health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 16 | $12,653 |
| Estradiol | 21 | $981 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $1,191 | $12,65316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 women's health providers in California.
Other women's health in Fresno
- Sena RowaidFresno$4K
- Nisha NairFresno$1K
- Barbara DehnMountain View$87K
- Zaruhi HarutyunyanWest Hollywood$55K
- Roberta MoradfarWest Hollywood$30K
- Patricia GeraghtyWalnut Creek$26K
- Katherine KetzStockton$26K
- Debbie BarishBerkeley$16K
- Raisa HowardEl Segundo$11K
- Mary FesselWoodland$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.